Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
The triplet therapy was effective only in patients with nonmutated PIK3CA and ESR1 genes, achieving a median PFS of 9.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback